Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/STAT1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/STAT1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/STAT1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/STAT1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/STAT1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAT1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAT1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAT1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STAT1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAT1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAT1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007137531 | Oral cavity | NEOLP | cellular response to peptide hormone stimulus | 60/2005 | 290/18723 | 3.92e-07 | 1.19e-05 | 60 |
GO:003434131 | Oral cavity | NEOLP | response to interferon-gamma | 36/2005 | 141/18723 | 5.06e-07 | 1.52e-05 | 36 |
GO:000283131 | Oral cavity | NEOLP | regulation of response to biotic stimulus | 65/2005 | 327/18723 | 5.93e-07 | 1.74e-05 | 65 |
GO:007135631 | Oral cavity | NEOLP | cellular response to tumor necrosis factor | 50/2005 | 229/18723 | 6.79e-07 | 1.93e-05 | 50 |
GO:004564623 | Oral cavity | NEOLP | regulation of erythrocyte differentiation | 18/2005 | 47/18723 | 6.84e-07 | 1.93e-05 | 18 |
GO:003286931 | Oral cavity | NEOLP | cellular response to insulin stimulus | 45/2005 | 203/18723 | 1.56e-06 | 3.86e-05 | 45 |
GO:004343431 | Oral cavity | NEOLP | response to peptide hormone | 76/2005 | 414/18723 | 1.79e-06 | 4.33e-05 | 76 |
GO:005079232 | Oral cavity | NEOLP | regulation of viral process | 38/2005 | 164/18723 | 3.25e-06 | 7.35e-05 | 38 |
GO:003320931 | Oral cavity | NEOLP | tumor necrosis factor-mediated signaling pathway | 27/2005 | 99/18723 | 3.40e-06 | 7.60e-05 | 27 |
GO:004865921 | Oral cavity | NEOLP | smooth muscle cell proliferation | 40/2005 | 184/18723 | 9.53e-06 | 1.82e-04 | 40 |
GO:003545631 | Oral cavity | NEOLP | response to interferon-beta | 13/2005 | 32/18723 | 1.14e-05 | 2.10e-04 | 13 |
GO:004866021 | Oral cavity | NEOLP | regulation of smooth muscle cell proliferation | 39/2005 | 180/18723 | 1.33e-05 | 2.37e-04 | 39 |
GO:190370632 | Oral cavity | NEOLP | regulation of hemopoiesis | 66/2005 | 367/18723 | 1.67e-05 | 2.83e-04 | 66 |
GO:00604855 | Oral cavity | NEOLP | mesenchyme development | 54/2005 | 291/18723 | 3.95e-05 | 5.62e-04 | 54 |
GO:004876214 | Oral cavity | NEOLP | mesenchymal cell differentiation | 46/2005 | 236/18723 | 4.18e-05 | 5.92e-04 | 46 |
GO:003286832 | Oral cavity | NEOLP | response to insulin | 50/2005 | 264/18723 | 4.35e-05 | 6.13e-04 | 50 |
GO:00358506 | Oral cavity | NEOLP | epithelial cell differentiation involved in kidney development | 15/2005 | 47/18723 | 7.12e-05 | 9.27e-04 | 15 |
GO:00308566 | Oral cavity | NEOLP | regulation of epithelial cell differentiation | 33/2005 | 154/18723 | 7.47e-05 | 9.67e-04 | 33 |
GO:005067323 | Oral cavity | NEOLP | epithelial cell proliferation | 73/2005 | 437/18723 | 7.74e-05 | 9.93e-04 | 73 |
GO:004852531 | Oral cavity | NEOLP | negative regulation of viral process | 23/2005 | 92/18723 | 7.87e-05 | 1.00e-03 | 23 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0516723 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
hsa0491916 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0516733 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
hsa0491917 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0514013 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0516941 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0516743 | Breast | DCIS | Kaposi sarcoma-associated herpesvirus infection | 38/846 | 194/8465 | 3.43e-05 | 3.69e-04 | 2.72e-04 | 38 |
hsa0491922 | Breast | DCIS | Thyroid hormone signaling pathway | 23/846 | 121/8465 | 1.78e-03 | 1.22e-02 | 9.00e-03 | 23 |
hsa0516951 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0516753 | Breast | DCIS | Kaposi sarcoma-associated herpesvirus infection | 38/846 | 194/8465 | 3.43e-05 | 3.69e-04 | 2.72e-04 | 38 |
hsa0491932 | Breast | DCIS | Thyroid hormone signaling pathway | 23/846 | 121/8465 | 1.78e-03 | 1.22e-02 | 9.00e-03 | 23 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0514514 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAT1 | SNV | Missense_Mutation | novel | c.567N>C | p.Lys189Asn | p.K189N | P42224 | protein_coding | tolerated(0.43) | benign(0.014) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
STAT1 | SNV | Missense_Mutation | | c.1778N>T | p.Asp593Val | p.D593V | P42224 | protein_coding | deleterious(0.03) | benign(0.392) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
STAT1 | SNV | Missense_Mutation | | c.1236G>C | p.Gln412His | p.Q412H | P42224 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT1 | insertion | Nonsense_Mutation | novel | c.65_66insAGGTT | p.Tyr22Ter | p.Y22* | P42224 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
STAT1 | insertion | Frame_Shift_Ins | novel | c.63_64insATCCCCATTTTAAAGATGAGAAAAC | p.Tyr22IlefsTer10 | p.Y22Ifs*10 | P42224 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
STAT1 | insertion | In_Frame_Ins | novel | c.46_47insGCCTGG | p.Leu15_Glu16insGlyLeu | p.L15_E16insGL | P42224 | protein_coding | | | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT1 | SNV | Missense_Mutation | novel | c.431G>T | p.Ser144Ile | p.S144I | P42224 | protein_coding | tolerated(0.18) | benign(0.021) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STAT1 | SNV | Missense_Mutation | novel | c.227A>G | p.Asn76Ser | p.N76S | P42224 | protein_coding | tolerated(0.13) | benign(0.023) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STAT1 | SNV | Missense_Mutation | | c.1035N>C | p.Leu345Phe | p.L345F | P42224 | protein_coding | deleterious(0.01) | possibly_damaging(0.629) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
STAT1 | SNV | Missense_Mutation | | c.1945N>T | p.Arg649Cys | p.R649C | P42224 | protein_coding | deleterious(0.03) | possibly_damaging(0.48) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | AVT-02 UE | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | PMID26394986-Compound-10 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Peptidomimetic analog 5 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | IPRIFLAVONE | IPRIFLAVONE | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | GARCINOL | GARCINOL | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | GUTTIFERONE K | GUTTIFERONE K | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Peptide analog 8 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Platinum IV complexe 1 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | Oxazole derivative 1 | | |
6772 | STAT1 | DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR, KINASE | | 10-METHOXYLRUTAECARPINE | CHEMBL85826 | |